Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
about
Crystal Structures of Wild-type and Mutant Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May Be Linked to Trimethoprim ResistanceTowards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductaseToward New Therapeutics for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of MRSA and Streptococcus pyogenesSystematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Antibiotic options for treating community-acquired MRSA.The determinants of the antibiotic resistance process.In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptidesThe MUT056399 inhibitor of FabI is a new antistaphylococcal compound.Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?Healthcare-associated pneumonia: principles and emerging concepts on management.Inhibitors of sterol biosynthesis as Staphylococcus aureus antibiotics.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.The evaluation and treatment of complicated skin and skin structure infections.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Winning the arms race by improving drug discovery against mutating targets.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Antifolate agents: a patent review (2010 - 2013).Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.Novel systemic antibiotics in dermatology.Treatment of Staphylococcus aureus Infections.Crystallization and preliminary X-ray analysis of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase from Staphylococcus aureus.Generation of a Novel Staphylococcus aureus Ghost Vaccine and Examination of Its Immunogenicity against Virulent Challenge in Rats.Double-disk synergy test for detection of synergistic effect between antibiotics against nosocomial strains of staphylococcus aureus.The challenge of developing robust drugs to overcome resistance.Optimizing delivery of care for patients with MRSA infection: focus on transitions of care.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Effect of oxazolidinone, RBx 7644 (ranbezolid), on inhibition of staphylococcal adherence to plastic surfaces.Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.Implant removal rate from infection after tibial plateau leveling osteotomy in dogs.Copper nanoparticles as an efflux pump inhibitor to tackle drug resistant bacteria
P2860
Q27653967-3E69927B-5DAE-474C-9646-3F485A1FA365Q27658737-27EF08BA-C00F-4F2B-B2A3-5EB5AD3896B9Q27677355-2E2DE918-5EA2-4517-92BA-CD3A17A710C2Q28078557-512A557D-EAB4-4C7C-A9D1-363BB220BB52Q34593646-E8CEB75E-E03F-47C5-8FDC-231DA41AC6D6Q35026542-E64374FB-EE0B-48D6-BDB4-E8FDCAE641DEQ35083990-E874F948-2B2F-43F6-B77E-59C94BC6CDB5Q35270339-4CD03372-A290-42F7-8EA8-B021C1C1AAFDQ36839693-BAE927C0-8D80-4A39-A1EC-00AB4913FB31Q37013020-B30C438E-990E-43A1-8FDF-D9E32E1D845FQ37016152-8A8DCF57-3B32-4A26-AB20-54B300E1EBCDQ37077629-06738FA1-DF8C-4E16-929B-9B1673262D09Q37111836-F1DDDF95-6F41-4EC2-976C-B342129E217CQ37252733-AF59B523-D3F6-43B5-9593-0A68C45D1CAFQ37952291-E627BB06-4C14-4BF9-AB8F-14E9712D8EA6Q38124842-53152EE0-DFB8-4E13-9213-4E140A30C400Q38198160-76A181EA-DEF7-4B67-88D2-B24638B9884BQ39520227-EC6DF431-F189-4D75-BDE5-0A11DCEF020AQ39616901-B82561F5-A3EE-4DC3-8D3E-2F991906E603Q40049973-B1A329CE-7FEA-4099-AA3E-6184F75D82DDQ40369763-C029FCC1-B0EA-4D7D-893A-C4364760121BQ41239476-07B5D1B5-72D2-412F-B5B9-A93C9721652BQ41559217-964E3838-4368-46EE-8594-231FE75E766DQ43221173-EFB57B22-E8B1-40E0-A5B2-5A01634C25EBQ45183500-876BC155-3DFA-4585-B85A-ED61A5165108Q46274310-59FA0E68-F38C-4F72-AAD5-DCE65B373BA3Q46448510-74416347-28A0-46CA-B536-01571E97322BQ46456918-A86F110F-B0D0-4391-A7E3-C0435989F54CQ48144625-64983D41-063E-4B76-80B3-32CF6183AC80Q57376854-A8D5B7BD-9572-499B-B184-26F4746E4733
P2860
Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Emerging options for treatment ...... phylococcus aureus infections.
@ast
Emerging options for treatment ...... phylococcus aureus infections.
@en
type
label
Emerging options for treatment ...... phylococcus aureus infections.
@ast
Emerging options for treatment ...... phylococcus aureus infections.
@en
prefLabel
Emerging options for treatment ...... phylococcus aureus infections.
@ast
Emerging options for treatment ...... phylococcus aureus infections.
@en
P2860
P356
P1433
P1476
Emerging options for treatment ...... phylococcus aureus infections.
@en
P2093
Richard H Drew
P2860
P304
P356
10.1592/PHCO.27.2.227
P407
P577
2007-02-01T00:00:00Z